Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …

Background Maintaining durable immunity following vaccination represents a major challenge,
but whether mRNA booster vaccination improves durability is unknown. Methods We …

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting
with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger …

We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna
mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen …

… Angela Branche, Nadine Rouphael, David Diemert, Ann Falsey, Cecilia Losada, Lindsey
(R) Baden, Sharon Frey, Jennifer Whitaker, Susan Little, Evan Anderson, Emmanuel Walter …

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting
with bivalent SARS-CoV-2 mRNA vaccines based on either BA. 1 or BA. 4/BA. 5 Omicron …

People living with HIV (PLH) experience higher rates of HPV infection as well as an increased
risk of HPV-related disease, including malignancies. Although they are considered a high-…

Background Respiratory infection caused by Pneumocystis jiroveci is a common opportunistic
infection in patients with human immunodeficiency virus (HIV) with CD4 counts< 200 cells/…

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting
with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger …